ALISO VIEJO, Calif.--(BUSINESS WIRE)--Valeant Pharmaceuticals International (NYSE:VRX) today announced that it is developing an intranasal form of delivery for diazepam for the treatment of seizure emergencies in children and adults, in conjunction with researchers from the University of Minnesota. Valeant currently markets Diastat® AcuDial™ (diazepam rectal gel) -- the only FDA approved at-home treatment for the acute management of increased seizure activity.
